What is sarilumab’s mechanism of action (MOA)?
Sarilumab is a human monoclonal antibody that targets the interleukin-6 (IL‑6) receptor (specifically the IL‑6 receptor alpha subunit). By blocking IL‑6 receptor signaling, it reduces downstream inflammatory activity driven by IL‑6. This is the core mechanism behind its anti-inflammatory effects in diseases where IL‑6 signaling is a major driver.
How does blocking the IL‑6 receptor affect inflammation?
IL‑6 is a cytokine that helps regulate immune and inflammatory responses. When IL‑6 binds its receptor, it triggers signaling pathways that promote inflammation and related immune processes. Sarilumab prevents IL‑6 from activating its receptor, which lowers inflammatory signaling and helps reduce disease activity.
Why does IL‑6 blockade work in conditions treated with sarilumab?
Diseases in which sarilumab is used involve cytokine-driven inflammation, and IL‑6 signaling contributes to symptoms and inflammatory biomarkers. By interrupting IL‑6 receptor signaling, sarilumab can dampen that inflammatory cascade and improve clinical outcomes.
Is sarilumab an IL‑6 “ligand blocker” or an IL‑6 “receptor blocker”?
Sarilumab is a receptor blocker (it binds the IL‑6 receptor). That distinguishes it from IL‑6 ligand–targeting approaches (which bind IL‑6 itself rather than the receptor). Both strategies aim to stop IL‑6 signaling, but the binding target differs.
How is sarilumab different from tocilizumab (related IL‑6 therapy)?
Tocilizumab is also an IL‑6 pathway monoclonal antibody used for similar inflammatory indications, and it also blocks the IL‑6 receptor. The practical differences between them tend to come down to product-specific clinical/regulatory details rather than the general MOA category (IL‑6 receptor inhibition).